Pluri Inc. (PLUR)
$0.94-3.09%Close
SELLCRISIS · day 34
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8M
- Beta
- 0.69
- P/E (TTM)
- -0.38
- Short % float
- 0.42%
- Days to cover
- 1.0
- SI change
- -3.0%
- 1W
- -5.05%
- 1M
- -24.19%
- vs SPY 1W
- -4.91%
- vs SPY 1M
- -26.70%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 9
- GROWTH
- 19
- GARP
- 8
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC86.8%
REV YoY-
ROE144.6%
EPS YoY-
ROA-98.3%
GROSS45
OP-2456
NET-2406
[VALUATION]
P/E TTM-0.38
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-0.44
P/FCF-
EV/EBITDA-1.73
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.27
ND/EBITDA-
BETA0.69
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on PLUR?
- LOPJLB’s latest quantitative signal on Pluri Inc. (PLUR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PLUR in?
- Pluri Inc. (PLUR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Pluri Inc. (PLUR) do?
- Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in adv…